Welcome to our dedicated page for Fate Therapeutic news (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutic stock.
Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company developing induced pluripotent stem cell (iPSC)-derived, off-the-shelf cellular immunotherapies for cancer and autoimmune diseases. This news page aggregates company press releases, clinical updates, financial disclosures, and corporate announcements so readers can follow how Fate Therapeutics’ iPSC-derived CAR T-cell and NK-cell programs progress over time.
Recent news from Fate Therapeutics has highlighted updated Phase 1 clinical data for FT819, its off-the-shelf CD19-targeted CAR T-cell product candidate for systemic lupus erythematosus (SLE), including reports of sustained reductions in disease activity scores, B-cell depletion with immune remodeling, and a favorable safety profile with less-intensive or no conditioning chemotherapy. The company has also issued news on regulatory authorizations to expand FT819 trials into the United Kingdom and European Union, initiation of dose-expansion cohorts in additional autoimmune diseases, and presentations at major medical meetings such as the American College of Rheumatology (ACR) Convergence and the American Society of Hematology (ASH) Annual Meeting.
In oncology, Fate Therapeutics’ news flow includes updates on FT825 / ONO-8250 for advanced HER2-positive solid tumors and FT836, a MICA/B-targeted CAR T-cell program being evaluated without conditioning chemotherapy, as well as preclinical progress on FT839, a dual CAR T-cell candidate co-targeting CD19 and CD38. Investors can also find quarterly financial results, details of corporate restructuring to streamline operations and extend cash runway, and information on executive appointments and employee inducement equity awards.
By reviewing the FATE news feed, readers can track clinical milestones, regulatory interactions, conference presentations, and corporate developments that shape the company’s iPSC-derived cell therapy pipeline. Bookmark this page for a consolidated view of Fate Therapeutics’ latest publicly released information.
Summary not available.
Summary not available.
Fate Therapeutics, a clinical-stage biopharmaceutical company, will host a conference call on May 3, 2023, at 5:00 PM ET to discuss its financial results for Q1 2023. The company is pioneering induced pluripotent stem cell (iPSC)-derived cellular immunotherapies aimed at treating cancer and autoimmune disorders. Participants can register for the call via a provided link and access the live webcast on the company’s website, under the 'Investors' section. An archived version of the webcast will be available shortly after the event. Fate Therapeutics specializes in multiplexed-engineered iPSC lines and aims to deliver innovative cell therapies that incorporate synthetic controls such as chimeric antigen receptors (CARs).
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical firm, will present at two upcoming investor conferences. The events include the 43rd Annual TD Cowen Health Care Conference on March 8, 2023, in Boston and the Barclays Global Healthcare Conference on March 14, 2023, in Miami. Live webcasts of these presentations will be available on the company's website. Fate Therapeutics is focused on developing innovative induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to treat cancer and autoimmune diseases, leveraging its proprietary iPSC product platform.
Fate Therapeutics reported key business highlights and financial results for Q4 and FY 2022, ending with approximately $475 million in cash and cash equivalents. The company initiated multi-dose treatment cohorts in the FT576 Phase 1 study for multiple myeloma, showing promising interim data with objective responses. Plans for 2023 include IND submissions for FT522 targeting B-cell lymphoma, FT819 for aggressive B-cell lymphoma, and FT825/ONO-8250 for solid tumors. The termination of the Janssen collaboration raises concerns, as does a planned workforce reduction, expected to incur $12-$16 million in costs. Total revenue for Q4 was $44.4 million, while R&D expenses were $87.2 million.
Fate Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: FATE), announced a conference call on February 28, 2023, at 5:00 PM ET to discuss its fourth quarter and full year 2022 financial results. The company is focused on developing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune disorders. Its pipeline includes off-the-shelf iPSC-derived natural killer (NK) cells and T-cell product candidates that aim to work alongside existing cancer treatments. Archived webcasts will be available post-event on the company's website.
Fate Therapeutics has ended 2022 with approximately $475 million in cash and cash equivalents, ensuring a funding runway through 2025. The company terminated its collaboration with Janssen Biotech and will wind down associated activities, focusing instead on developing its innovative NK and CAR T-cell programs. Key advancements include the second-generation CD19-targeted CAR NK cell program and ongoing Phase 1 studies for FT576 and FT819. The strategic shift aims to enhance clinical applications while reducing operational costs, including workforce reductions.
Fate Therapeutics showcased innovative preclinical data at the 64th ASH Annual Meeting, focusing on strategies to enhance the effectiveness of iPSC-derived cancer immunotherapies without conditioning chemotherapy. These strategies include the introduction of an alloimmune defense receptor, genetic ablation of CD38, and dual knockouts of CD54 and CD58, aimed at improving the persistence and anti-tumor activity of engineered NK cells. The findings suggest a significant leap toward safer, off-the-shelf cell therapies for hematologic malignancies and solid tumors.
Fate Therapeutics presented promising interim Phase 1 data for its BCMA-targeted product candidate, FT576, at the 64th American Society of Hematology Annual Meeting. The trial showed encouraging clinical activity in patients with relapsed/refractory multiple myeloma, with no instances of cytokine release syndrome. Initial results indicated that patients treated with FT576 in combination with daratumumab experienced substantial reductions in soluble BCMA levels. Additionally, the company highlighted preclinical data for FT555, its GPRC5D-targeted candidate, which demonstrated effective tumor regression in aggressive myeloma models.
Fate Therapeutics presented interim clinical data for FT819, its novel CAR T-cell therapy, at the American Society of Hematology meeting. This Phase 1 trial targets relapsed/refractory large B-cell lymphoma with promising results. As of September 8, 2022, of 10 treated patients, 3 achieved complete responses (CR) after a single dose. Notably, FT819 exhibited a favorable safety profile with no serious adverse events. Its unique iPSC-derived platform enhances production consistency and accessibility for patients. The ongoing trial seeks to establish optimum dosing and further evaluate efficacy.